Category: Interviews
Andrea Maier on Longevity Medicine for All
October 22, 2025
Dr. Andrea Maier, Oon Chiew Seng Professor in Medicine at the National University of Singapore, is a veteran geroscientist and one of the most familiar faces in the rising field
Sam Sharifi on Fixing Our DNA
October 3, 2025
Among the hallmarks of aging, DNA damage is both one of the most important and one of the hardest to crack. A couple of years ago, when I first learned
Joe Betts-Lacroix on Retro Bio and Its Recent AI Advancement
October 2, 2025
Retro Biosciences, one of the hottest startups in the longevity field, was founded about five years ago by the tech entrepreneur Joe Betts-Lacroix with a $180 million investment from his
Nir Barzilai: “Positive Evidence for Metformin is Mountingâ€
August 12, 2025
Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine, among his many other titles, is one of geroscience’s most prominent figures.
Gabriel Cian on Investment and the 2060 Longevity Forum
July 10, 2025
In this Lifespan interview, we speak with Gabriel Cian, founder of the 2060 Longevity Forum, about how his background in software shaped his views on healthspan innovation, the forum’s approach
Dr. David Furman on Inflammation and Aging
July 7, 2025
The longevity field hasn’t been very good at naming things, but one notable exception is “inflammagingâ€: the low-grade chronic inflammation that correlates with aging. Recognition has been growing that inflammation,
Boyang Wang on Targeting Underfunded Longevity Projects
June 9, 2025
In this interview, Boyang Wang of Immortal Dragons discusses the kinds of projects he wants to fund, ways in which the industry can be encouraged to develop, relationships between the
Rejuve.AI: Just Another App or a Longevity Research Network?
June 5, 2025
On its website, Rejuve.AI, a company co-founded by its dynamic CEO, Jasmine Smith, and a renowned AI researcher, Ben Goertzel, promises a lot of things: to “democratize longevity, globally,†to
Michael Levin on Bioelectricity in Development and Aging
May 8, 2025
Michael Levin, professor at Tufts University and director of Allen Discovery Center, has been working for years on how bioelectrical patterns affect development and aging. His research proves that this
Joshua “Scotch†McClure: “Infectious Disease Drives Agingâ€
March 24, 2025
Like many people, I’m both wary of and intrigued by people who make bombastic claims. Years in the longevity field have taught me caution but also that big claims are
Junevity Is Silencing RNA to Treat Obesity and Diabetes
February 27, 2025
Some longevity biotech companies fit neatly into one of the big buckets we have in this field, like senolytics or cellular reprogramming. Others, such as Junevity, a small spin-out from
Marco Quarta on Cellular Senescence in Aging
January 24, 2025
Dr. Marco Quarta runs one of the most interesting start-ups in the longevity field: Rubedo, which focuses on utilizing the senolytic approach to cellular senescence. This company has developed ingenious
Cyclarity Launches Human Trial to Cure Atherosclerosis
January 23, 2025
Recently, Cyclarity Therapeutics announced the launch of a Phase 1 human clinical trial for a drug that aims to remove the arterial plaques that lead to heart attacks and strokes.
Why Research Teams Should Email XPRIZE Healthspan Now
December 13, 2024
With the deadline for submissions just around the corner, Jamie Justice, Executive Director of XPRIZE HealthSpan, explains to researchers still on the fence why they should contact her team now
Mehmood Khan on Aging Policy and Collaboration
December 3, 2024
I first met Dr. Mehmood Khan in 2022 at the inaugural Longevity Summit Dublin, where organizers Aubrey de Grey and Martin O’Dea made a bold decision to include policy and
Andrea Maier on Longevity Medicine for All
October 22, 2025
Dr. Andrea Maier, Oon Chiew Seng Professor in Medicine at the National University of Singapore, is a veteran geroscientist and one of the most familiar faces in the rising field of longevity medicine, which aims to translate the early successes of geroscience into clinical practice. Parallel
Sam Sharifi on Fixing Our DNA
October 3, 2025
Among the hallmarks of aging, DNA damage is both one of the most important and one of the hardest to crack. A couple of years ago, when I first learned about Matter Bioworks at a prominent longevity conference, I was amazed at the audacity of the
Joe Betts-Lacroix on Retro Bio and Its Recent AI Advancement
October 2, 2025
Retro Biosciences, one of the hottest startups in the longevity field, was founded about five years ago by the tech entrepreneur Joe Betts-Lacroix with a $180 million investment from his friend Sam Altman, the CEO of OpenAI. Despite its hefty war chest, the company initially pursued
Nir Barzilai: “Positive Evidence for Metformin is Mountingâ€
August 12, 2025
Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine, among his many other titles, is one of geroscience’s most prominent figures. He is everywhere all at once, seemingly collaborating with the entire world, but is best known
Gabriel Cian on Investment and the 2060 Longevity Forum
July 10, 2025
In this Lifespan interview, we speak with Gabriel Cian, founder of the 2060 Longevity Forum, about how his background in software shaped his views on healthspan innovation, the forum’s approach to scientific and investment credibility, and what he sees as the biggest bottlenecks and opportunities facing
Dr. David Furman on Inflammation and Aging
July 7, 2025
The longevity field hasn’t been very good at naming things, but one notable exception is “inflammagingâ€: the low-grade chronic inflammation that correlates with aging. Recognition has been growing that inflammation, the ubiquitous reaction of the immune system to various stressors, is a major driver of many
Boyang Wang on Targeting Underfunded Longevity Projects
June 9, 2025
In this interview, Boyang Wang of Immortal Dragons discusses the kinds of projects he wants to fund, ways in which the industry can be encouraged to develop, relationships between the East and West in longevity research and development, and what got him involved in longevity. Hello,
Rejuve.AI: Just Another App or a Longevity Research Network?
June 5, 2025
On its website, Rejuve.AI, a company co-founded by its dynamic CEO, Jasmine Smith, and a renowned AI researcher, Ben Goertzel, promises a lot of things: to “democratize longevity, globally,†to enable you to “take control of your data, and harness its earning potential,†and to “unite
Michael Levin on Bioelectricity in Development and Aging
May 8, 2025
Michael Levin, professor at Tufts University and director of Allen Discovery Center, has been working for years on how bioelectrical patterns affect development and aging. His research proves that this often-overlooked part of biology is immensely important and that mastering its mechanisms might one day do
Joshua “Scotch†McClure: “Infectious Disease Drives Agingâ€
March 24, 2025
Like many people, I’m both wary of and intrigued by people who make bombastic claims. Years in the longevity field have taught me caution but also that big claims are not necessarily outlandish, and few people make bigger claims than Joshua “Scotch†McClure, founder and CEO
Junevity Is Silencing RNA to Treat Obesity and Diabetes
February 27, 2025
Some longevity biotech companies fit neatly into one of the big buckets we have in this field, like senolytics or cellular reprogramming. Others, such as Junevity, a small spin-out from the University of California, San Francisco, dare to walk an unbeaten path. Junevity pursues the ambitious
Marco Quarta on Cellular Senescence in Aging
January 24, 2025
Dr. Marco Quarta runs one of the most interesting start-ups in the longevity field: Rubedo, which focuses on utilizing the senolytic approach to cellular senescence. This company has developed ingenious ways to cope with the notorious heterogeneity of senescent cells and is one of the first
Cyclarity Launches Human Trial to Cure Atherosclerosis
January 23, 2025
Recently, Cyclarity Therapeutics announced the launch of a Phase 1 human clinical trial for a drug that aims to remove the arterial plaques that lead to heart attacks and strokes. Tackling the leading cause of death worldwide Cyclarity Therapeutics is working on a cost-effective small molecule
Why Research Teams Should Email XPRIZE Healthspan Now
December 13, 2024
With the deadline for submissions just around the corner, Jamie Justice, Executive Director of XPRIZE HealthSpan, explains to researchers still on the fence why they should contact her team now but also why missing the deadline is not the end of the world. XPRIZE Foundation has
Mehmood Khan on Aging Policy and Collaboration
December 3, 2024
I first met Dr. Mehmood Khan in 2022 at the inaugural Longevity Summit Dublin, where organizers Aubrey de Grey and Martin O’Dea made a bold decision to include policy and advocacy discussions alongside the traditional focus on longevity research. Like many others in the audience, I